Dashboard
$DCOYJul 15, 2026, 1:25 PMAI processed

Decoy Therapeutics (DCOY) elects ex‐Moderna leader Patricia Gauthier to board

AI Summary

Decoy Therapeutics (NASDAQ: DCOY) said stockholders elected Patricia Gauthier, former Moderna SVP and ex‐GSK leader, as a Class II director at its July 14, 2026 annual meeting. The company says her commercialization, manufacturing and market‐access experience will help advance Decoy's Designable Multi‐Antiviral (D‐MAV) programs toward the clinic.

Positives

  • Patricia Gauthier elected as Class II director at the July 14, 2026 annual meeting
  • Gauthier brings senior commercial and biomanufacturing experience from Moderna and prior GSK roles
  • Company states her expertise will support moving D‑MAV antiviral programs toward clinical development

Negatives

  • Press release does not announce any operational, financing or equity‑grant actions tied to the appointment
  • Release contains forward‑looking statements noting financing and IND process risks
  • No changes to clinical timelines or program milestones were reported